Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Funding to support exploration of TXA-127 for epidermolysis bullosa

March 4, 2019

Foamix presents positive safety and efficacy data from phase III study of FMX-103

Feb. 28, 2019

FunPep gains Australian clearance for phase I/IIa study of FPP-003

Feb. 27, 2019

Salt plays role in dermatitis risk

Feb. 26, 2019

Dermira initiates proof-of-concept study with Qbrexza in primary palmar hyperhidrosis

Feb. 25, 2019

Tapinarof demonstrates safety and efficacy in phase II study in plaque psoriasis

Feb. 25, 2019

Humira becomes the first treatment in Japan to be approved for hidradenitis suppurativa

Feb. 22, 2019

Study evaluates nitisinone for 1 year in patients with oculocutaneous albinism

Feb. 21, 2019

Novartis discloses new FOXO3 inhibitors and RAC activators

Feb. 19, 2019

Patient enrollment is ongoing in Akros Pharma's phase II study of JTE-451

Feb. 18, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...